Surufatinib with chemo-immunotherapy and chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
A Prospective, Single-arm, Phase II Clinical Trial of Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This trial will test whether adding surufatinib to two cycles of chemo-immunotherapy followed by concurrent chemoradiotherapy helps people with unresectable, locally advanced esophageal squamous cell carcinoma.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 69 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | surufatinib, chemotherapy, immunotherapy, toripalimab |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT07086469 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-arm phase II trial enrolling patients with unresectable, locally advanced esophageal squamous cell carcinoma. Participants will receive two cycles of neoadjuvant therapy (albumin-bound paclitaxel, cisplatin, toripalimab, and surufatinib) followed by definitive concurrent chemoradiotherapy. The study will track tumor response, progression-free and overall survival, and safety using scheduled imaging, endoscopic assessments, and standard adverse-event reporting. Outcomes will be compared to historical expectations for this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults (18–80 years) with histologically confirmed, locally advanced unresectable ESCC (T2–4, N0–3, M0, or M1 limited to supraclavicular nodes), ECOG performance status 0–1, adequate organ function, and no prior systemic or local therapy.
Not a fit: Patients with widespread metastatic disease beyond limited supraclavicular nodes, prior chemotherapy/radiation/targeted/immunotherapy, poor performance status, or significant organ dysfunction are unlikely to qualify or benefit.
Why it matters
Potential benefit: If successful, the regimen could improve tumor control and survival for patients with unresectable locally advanced ESCC.
How similar studies have performed: PD‑1 inhibitors plus chemotherapy have shown benefit in ESCC, but combining surufatinib with this neoadjuvant chemo‑immunotherapy followed by concurrent chemoradiotherapy is a novel approach without published phase II results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC). * Locally advanced, unresectable esophageal cancer assessed by endoscopic ultrasound and imaging studies, including esophagography, contrast-enhanced CT scans of the lower neck, chest, and upper abdomen, MRI of the lower neck and chest, whole-body bone scintigraphy, or PET/CT; staged as T2-4, N0-3, M0-1 (M1 limited to supraclavicular lymph node metastasis). * Male or female patients aged 18 to 80 years. * No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy. * Expected life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ and bone marrow function defined as: Forced expiratory volume in one second (FEV1) ≥ 1000 mL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. * Signed and dated informed consent form must be obtained prior to any study-related procedures. Exclusion Criteria: * Participation in another clinical trial simultaneously, except for observational (non-interventional) studies. * Prior use of any targeted therapy. * Major surgery within 4 weeks prior to study entry (excluding vascular access procedures). * Uncontrolled comorbidities, including but not limited to active or ongoing infections, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, arrhythmias, active peptic ulcer disease or gastritis, intestinal perforation, bowel obstruction, active bleeding disorders, or psychiatric/social conditions that may impair compliance with study requirements or the ability to provide informed consent. * Performance status (PS) score of 2-4. * Presence of any of the following organ or bone marrow dysfunctions: Forced expiratory volume in one second (FEV1) \< 1000 mL; Absolute neutrophil count (ANC) \< 1.5 × 10⁹/L; Platelet count \< 100 × 10⁹/L; Hemoglobin \< 90 g/L; Creatinine clearance \< 50 mL/min calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin \> 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5 × ULN. * Any condition that may interfere with the assessment of efficacy or safety of surufatinib.
Where this trial is running
Guangzhou, Guangdong
- Sun yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Hui Liu — Sun yat-sen universtiy cancer center
- Study coordinator: Bo Qiu
- Email: qiubo@sysucc.org.cn
- Phone: +862087343031
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.